Except phosgenation and fluorination, Suven Pharma is capable of handling every other chemistry. This adds to the scope for contract engagements in speciality chemicals and clinical development for pharma

Buy Gland Pharma: target of Rs 3040: Sharekhan

Sharekhan is bullish on Gland Pharma has recommended buy rating on the stock with a target price of Rs 3040 in its research report dated February 26, 2021.

Weekly Tactical Pick | Aurobindo Pharma

Valuation at a discount to peers, but significant scope for margin improvement

Aurobindo Pharma: Vaccine and API plans inject add-on growth levers

In the injectables space, Aurobindo Pharma remains constructive and targets to almost double from current annual sales base of $380 million to $650-700 million in three years backed by new plants in the US and Vizag

Gland Pharma Q3: Strong and clean play on global generic injectables; accumulate

We believe dominance of profit/royalty-sharing aspect in the business model distinguishes Gland Pharma from other contract manufacturers

Gland Pharma IPO: Much more than a Heparin play; subscribe

Gland Pharma's IPO provides an opportunity to take exposure to a steady earnings compounder with strong credentials